GlobalData

Colorectal Cancer: Competitive Landscape to 2026

Colorectal cancer (CRC) originates in the colon or rectum, and is the fourth leading cause of mortality among cancer patients worldwide.

The CRC pipeline is highly active and evolving. 8% of oncology’s R&D efforts are focused on CRC, and there have been 4,827 investigatory clinical trials focusing on CRC across the globe. As of May 2018, the CRC pipeline featured more than 850 products across all stages of clinical development. EGFR and VEGF inhibitors remain a key focus, particularly in regards to biosimilar development.

This report will allow you to access invaluable data on the biosimilars market.

Doctor
  • Report Scope:
  • Pipeline Assessment – regional breakdown
  • Clinical Trials Assessment – trial breakdown by phase
  • Commercial Assessment – leading marketed products, current and future players
  • Competitive Landscape Analysis – key market events to 2026

GlobalData’s Biosimilars market report shows that CRC clinical trials have demonstrated high enrolment efficiencies. Due to the high prevalence of CRC, Phase III trials are large, and recruited an average of 680 subjects. Immunotherapy has offered diversity to the landscape with the recent launches of Keytruda and Opdivo in the US, and novel kinase inhibitors such as encorafenib + binimetinib will provide targeted therapies for currently underserved patient populations.

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Buy this report

Single user $ 3,495


Buy Now


reportstore@globaldata.com

+44 (0) 161 359 5813


Not ready to buy yet? Download our free report series guide on the Biosimilars Market

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.